LY4005130 for adults with non-segmental vitiligo

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial gives adult participants with non-segmental vitiligo intravenous LY4005130 or placebo and follows them for tolerability and adverse events. Blood tests will be used to track how the body processes the drug and any biological effects. Eligible participants must have had vitiligo for at least 3 months, 4–60% body surface involvement (with ≥0.5% on the face) and minimum F‑VASI and T‑VASI scores, and may have active or stable disease. The total participation period is about 48 weeks including screening, with visits at dermatology research centers in Arizona and California.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eligible participants must have the following at both screening and baseline:

  * A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months
  * Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet
  * BSA involvement of ≥0.5% on the face
  * F-VASI ≥0.5 and T-VASI ≥3, and
  * Either active or stable disease at both screening and baseline

Exclusion Criteria:

* Participants who have other types of vitiligo that are not considered active or stable vitiligo
* Currently have active forms of other disorders of pigmentation
* Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment
* Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved
* Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening
* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data
* Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve

Where it's running

• Medical Dermatology Specialists
  Phoenix, Arizona, United States Recruiting
• Saguaro Dermatology - Phoenix
  Phoenix, Arizona, United States Recruiting
• Center For Dermatology Clinical Research, Inc.
  Fremont, California, United States Recruiting
• Northridge Clinical Trials
  Northridge, California, United States Recruiting
• Cura Clinical Research - Oxnard
  Oxnard, California, United States Recruiting
• Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway
  Santa Clarita, California, United States Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• crisaborole 2% versus tacrolimus 0.1% with light therapy for facial vitiligo

  This study tests whether applying crisaborole 2% ointment can improve stable facial vitiligo in children and adults and whether it is as safe and effective as tacrolimus 0.1% when combined with light therapy.

  Recruiting Phase 3 Cairo University · Cairo · NCT07904910

• D-2570 in Non-Segmental Vitiligo (Phase 2)

  This study tests whether D-2570 can improve skin discoloration in adults with non-segmental vitiligo compared with a placebo.

  Recruiting Phase 2 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07625891

• EB06 vs placebo for adults with non-segmental vitiligo

  This study tests whether EB06 given by IV can safely and effectively help adults with moderate to severe non-segmental vitiligo compared with placebo.

  Recruiting Phase 2 Edesa Biotech Inc. · Edmonton, Alberta and 4 other locations · NCT07889492

• Imaging vitiligo lesions with polarized, sub-ultraviolet, and ultraviolet dermoscopy

  This study tests whether advanced light-based skin imaging can reveal details of vitiligo spots in adults more clearly than standard polarized dermoscopy.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07846969

• MH004 Ointment in non-segmental vitiligo: a phase 3 trial

  A 12-month randomized trial tests MH004 ointment to see if it helps facial vitiligo more than a placebo in people aged 12 to 75.

  Recruiting Phase 3 Minghui Pharmaceutical (Hangzhou) Ltd · Beijing, Beijing Municipality · NCT07682506

• Ruxolitinib Cream Plus Corticosteroids for Facial Non-Segmental Vitiligo in Real-World Practice

  This real-world study tests whether adding 1.5% ruxolitinib cream to corticosteroids helps people 12 and older with active facial non-segmental vitiligo.

  Recruiting at 6 sites Dermavon Holdings Limited · Shenzhen, Guangdong and 19 other locations · NCT07673640

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.